Chinese National Consensus Committee of Experts on Kawasaki Disease and Chinese Journal of Contemporary Pediatrics: The expert consensuses on Intravenous Immunoglobulin, aspirin, and Glucocorticoid
Abstract Kawasaki disease (KD) is an acute vasculitis with unknown etiology usually occurring in children under 5 years old. It is one of the common acquired heart diseases in children and can cause serious complications such as coronary injury. Although Intravenous immunoglobulin (IVIG) combined with oral aspirin (Asp) is currently recognized as the most effective treatment in KD acute stage and also the first-line treatment to prevent the cardiovascular complications of KD, Glucocorticoid (GC) is mainly used for KD patients with the high risk of Coronary artery aneurysm, no immunoglobulin response and confirmed Coronary artery aneurysm (CAA). There are already consensus guidelines on the diagnosis and treatment of KD at home and abroad, but there are inconsistent opinions in the literature on the mechanism, optimal timing, and dosage of drug treatment for KD. This article will summarize the three consensuses. This review will summarize three consensus items..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 18. Juli Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shuying, Ren [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-1865782/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA036551813 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA036551813 | ||
| 003 | DE-627 | ||
| 005 | 20230429185209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220719s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-1865782/v1 |2 doi | |
| 035 | |a (DE-627)XRA036551813 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-1865782/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Shuying, Ren |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chinese National Consensus Committee of Experts on Kawasaki Disease and Chinese Journal of Contemporary Pediatrics: The expert consensuses on Intravenous Immunoglobulin, aspirin, and Glucocorticoid |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Kawasaki disease (KD) is an acute vasculitis with unknown etiology usually occurring in children under 5 years old. It is one of the common acquired heart diseases in children and can cause serious complications such as coronary injury. Although Intravenous immunoglobulin (IVIG) combined with oral aspirin (Asp) is currently recognized as the most effective treatment in KD acute stage and also the first-line treatment to prevent the cardiovascular complications of KD, Glucocorticoid (GC) is mainly used for KD patients with the high risk of Coronary artery aneurysm, no immunoglobulin response and confirmed Coronary artery aneurysm (CAA). There are already consensus guidelines on the diagnosis and treatment of KD at home and abroad, but there are inconsistent opinions in the literature on the mechanism, optimal timing, and dosage of drug treatment for KD. This article will summarize the three consensuses. This review will summarize three consensus items. | ||
| 700 | 1 | |a Fangming, Deng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhongdong, Du |e verfasserin |4 aut | |
| 700 | 1 | |a Xiaodong, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Lijian, Xie |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Wang |e verfasserin |4 aut | |
| 700 | 1 | |a Fuyong, Jiao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 18. Juli |
| 773 | 1 | 8 | |g year:2022 |g day:18 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-1865782/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 18 |c 07 | ||
| 953 | |2 045F |a 570 | ||